Florence Suzan
Vitry-sur-seine, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Erratum: Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 08, 2025
Plain language summary on subcutaneous administration of isatuximab in people with relapsed and/or refractory multiple myeloma.
Journal: Future oncology (London, England)
Published: July 17, 2025
Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma: results of the Phase 2 study IZALCO.
Journal: Blood cancer journal
Published: July 08, 2025
Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 03, 2025
Subcutaneous administration of isatuximab in patients with multiple myeloma by an on-body delivery system: results of a nurse survey.
Journal: Frontiers in oncology
Published: December 17, 2024
A multicenter, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma.
Journal: Haematologica
Published: May 19, 2024
Profile of Women Initiated on Denosumab and Pattern of Use in a Restricted Postmenopausal Osteoporosis Indication: A French Database Analysis Over the Period 2013-2014.
Journal: Advances in therapy
Published: January 14, 2019
Health-Related Quality of Life of Patients With Multiple Myeloma Treated in Routine Clinical Practice in France.
Journal: Clinical lymphoma, myeloma & leukemia
Published: May 10, 2018
Going the distance: Are we losing patients along the multiple myeloma treatment pathway?
Journal: Critical reviews in oncology/hematology
Published: October 26, 2017
A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma.
Journal: Critical reviews in oncology/hematology
Published: April 25, 2017
Management of immune thrombocytopenia in adults: a population-based analysis of the French hospital discharge database from 2009 to 2012.
Journal: British journal of haematology
Published: December 22, 2014
Showing 1-12 of 12
Last Updated: 09/26/2026